Lisata Therapeutics, Inc.
LSTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000320017
No open-market purchases or sales by Lisata Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $3.70M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Lisata Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −2 vs. Q1 2025
- Shares held
- 782.5K
- −867 (−0.1%) vs. Q1 2025
- Total value
- $2.26M
- +$416.8K (+22.6%) vs. Q1 2025
- New holders
- 2
- 5 more added
- Sold out
- 4
- 3 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LSTA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $3.70M |
| Q1 2026 | 34 | $7.06M |
| Q4 2025 | 25 | $1.36M |
| Q3 2025 | 21 | $1.93M |
| Q2 2025 | 20 | $2.26M |
| Q1 2025 | 22 | $1.84M |
| Q4 2024 | 21 | $2.33M |
| Q3 2024 | 20 | $2.30M |
| Q2 2024 | 22 | $2.61M |
| Q1 2024 | 21 | $2.30M |
| Q4 2023 | 22 | $2.03M |
| Q3 2023 | 21 | $1.46M |
| Q2 2023 | 22 | $2.51M |
| Q1 2023 | 21 | $2.08M |
| Q4 2022 | 24 | $1.83M |
| Q3 2022 | 22 | $2.17M |
| Q2 2022 | 36 | $5.00M |
| Q1 2022 | 34 | $6.13M |
| Q4 2021 | 36 | $7.33M |
| Q3 2021 | 34 | $9.41M |
| Q2 2021 | 29 | $10.1M |
| Q1 2021 | 33 | $12.9M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Lisata Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 254,182 | $732.0K | 0.00% | 00.0% | Unchanged |
| BML Capital Management, LLC | 209,814 | $608.3K | 0.47% | −7,039−3.2% | Reduced |
| Renaissance Technologies LLC | 102,822 | $298.1K | 0.00% | +100+0.1% | Added |
| Geode Capital Management, LLC | 61,082 | $176.0K | 0.00% | +553+0.9% | Added |
| BlackRock, Inc. | 54,857 | $159.0K | 0.00% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 25,793 | $74.3K | 0.00% | +571+2.3% | Added |
| State Street Corp | 14,348 | $41.3K | 0.00% | 00.0% | Unchanged |
| Cerity Partners LLC | 12,183 | $32.3K | 0.00% | +12,183 | New |
| Bank of America Corp | 10,421 | $30.2K | 0.00% | +8+0.1% | Added |
| Northern Trust Corp | 10,268 | $29.8K | 0.00% | 00.0% | Unchanged |
| HighTower Advisors, LLC | 10,042 | $29.1K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 7,069 | $20.5K | 0.00% | +7,068+706,800.0% | Added |
| Royal Bank of Canada | 5,912 | $17.0K | 0.00% | 00.0% | Unchanged |
| Founders Capital Management | 2,000 | $5.80K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,323 | $3.84K | 0.00% | −884−40.1% | Reduced |
| Morgan Stanley | 224 | $649 | 0.00% | −1,242−84.7% | Reduced |
| SBI Securities Co., Ltd. | 140 | $406 | 0.00% | 00.0% | Unchanged |
| Raymond James Financial Inc | 6 | $17 | 0.00% | +6 | New |
| Barclays PLC | 4 | $12 | 0.00% | 00.0% | Unchanged |
| Cheviot Value Management, LLC | 3 | $8 | 0.00% | 00.0% | Unchanged |
| Cook Wealth Management Group LLC | 0 | $0 | 0.00% | −12,175−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −13−100.0% | Sold out |
| Loring Wolcott & Coolidge Fiduciary Advisors LLP | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −1−100.0% | Sold out |